{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:40:14Z","timestamp":1763037614466,"version":"build-2065373602"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.dmpk.2021.100403","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T13:31:37Z","timestamp":1620048697000},"page":"100403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Reduced theophylline clearance due to hepatic congestion secondary to right heart failure - A population pharmacokinetic study"],"prefix":"10.1016","volume":"41","author":[{"given":"Yasuo","family":"Kurata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Muraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Ieiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.dmpk.2021.100403_bib1","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1164\/ajrccm\/147.3.518","article-title":"Theophylline--an immunomodulatory role in asthma?","volume":"147","author":"Ward","year":"1993","journal-title":"Am Rev Respir Dis"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100403_bib2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1183\/09031936.94.07030579","article-title":"Theophylline in the management of asthma: time for reappraisal?","volume":"7","author":"Barnes","year":"1994","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.dmpk.2021.100403_bib3","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1164\/ajrccm.151.6.7767539","article-title":"Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy","volume":"151","author":"Kidney","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.dmpk.2021.100403_bib4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00003088-199325060-00007","article-title":"Theophylline target concentration in severe airways obstruction - 10 or 20 mg\/L? A randomised concentration-controlled trial","volume":"25","author":"Holford","year":"1993","journal-title":"Clin Pharmacokinet"},{"issue":"5 Pt 1","key":"10.1016\/j.dmpk.2021.100403_bib5","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/cpt1976195part1546","article-title":"Effect of smoking on theophylline disposition","volume":"19","author":"Hunt","year":"1976","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100403_bib6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt1977213310","article-title":"Theophylline kinetics in acute pulmonary edema","volume":"21","author":"Piafsky","year":"1977","journal-title":"Clin Pharmacol Ther"},{"issue":"8074","key":"10.1016\/j.dmpk.2021.100403_bib7","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S0140-6736(78)90305-7","article-title":"Altered theophylline pharmacokinetics during acute respiratory viral illness","volume":"1","author":"Chang","year":"1978","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.dmpk.2021.100403_bib8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2125.1982.tb02018.x","article-title":"Pharmacokinetic interaction between theophylline and erythromycin","volume":"14","author":"Iliopoulou","year":"1982","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100403_bib9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003088-198308030-00004","article-title":"Pharmacokinetic drug interactions with propranolol","volume":"8","author":"Wood","year":"1983","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmpk.2021.100403_bib10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/BF00544240","article-title":"Pharmacokinetics of theophylline in hyperthyroid and hypothyroid patients with chronic obstructive pulmonary disease","volume":"33","author":"Pokrajac","year":"1987","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmpk.2021.100403_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00609434","article-title":"Sex-related differences in theophylline pharmacokinetics","volume":"37","author":"Nafziger","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmpk.2021.100403_bib12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2165\/00003088-199120010-00005","article-title":"Pharmacokinetic interactions between theophylline and other medication (Part I)","volume":"20","author":"Upton","year":"1991","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.dmpk.2021.100403_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0002-9343(91)90075-9","article-title":"A\u00a0prospective evaluation of elevated serum theophylline concentrations to determine if high concentrations are predictable","volume":"91","author":"Greenberger","year":"1991","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100403_bib14","first-page":"229","article-title":"Theophylline disposition in acutely ill hospitalized patients. The effect of smoking, heart failure, severe airway obstruction, and pneumonia","volume":"118","author":"Powell","year":"1978","journal-title":"Am Rev Respir Dis"},{"issue":"11","key":"10.1016\/j.dmpk.2021.100403_bib15","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/jps.2600681106","article-title":"Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol","volume":"68","author":"Jusko","year":"1979","journal-title":"J\u00a0Pharmacol Sci"},{"issue":"21","key":"10.1016\/j.dmpk.2021.100403_bib16","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/BF01496473","article-title":"Theophylline elimination in congestive heart failure","volume":"61","author":"Kuntz","year":"1983","journal-title":"Klin Wochenschr"},{"issue":"4","key":"10.1016\/j.dmpk.2021.100403_bib17","first-page":"274","article-title":"Theophylline clearance in obese patients in relation to smoking and congestive heart failure","volume":"17","author":"Slaughter","year":"1983","journal-title":"Drug Intell Clin Pharm"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100403_bib18","first-page":"113","article-title":"Application of population pharmacokinetics to the optimization of theophylline therapy","volume":"21","author":"Otero","year":"1996","journal-title":"J\u00a0Clin Pharm Therapeut"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100403_bib19","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S0022-3565(25)09644-2","article-title":"Right heart failure impairs hepatic oxygenation and theophylline clearance in rats","volume":"273","author":"Ng","year":"1995","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"issue":"4","key":"10.1016\/j.dmpk.2021.100403_bib20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0090-9556(25)06585-7","article-title":"Effects of chronic left ventricular failure on hepatic oxygenation and theophylline elimination in the rat","volume":"23","author":"Angus","year":"1995","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmpk.2021.100403_bib21","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","article-title":"JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure - digest version","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ J"},{"issue":"8","key":"10.1016\/j.dmpk.2021.100403_bib22","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1253\/circj.CJ-66-0068","article-title":"Guidelines for treatment of acute heart failure (JCS 2011)","volume":"77","year":"2013","journal-title":"Circ J"},{"issue":"16","key":"10.1016\/j.dmpk.2021.100403_bib23","first-page":"e240","article-title":"ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.dmpk.2021.100403_bib24","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100403_bib25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/j.1552-4604.1997.tb04766.x","article-title":"Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update","volume":"37","author":"Yukawa","year":"1997","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmpk.2021.100403_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s002280100274","article-title":"Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-trough screen analysis","volume":"57","author":"Suematsu","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100403_bib27","first-page":"329","article-title":"Effect of obesity on serum amiodarone concentration in Japanese patients: population pharmacokinetic investigation by multiple trough screen analysis","volume":"34","author":"Fukuchi","year":"2009","journal-title":"J\u00a0Clin Pharm Therapeut"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100403_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40262-012-0029-2","article-title":"Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously)","volume":"52","author":"Ogawa","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.dmpk.2021.100403_bib29","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s40262-014-0189-3","article-title":"Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally)","volume":"53","author":"Ogawa","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.dmpk.2021.100403_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","article-title":"Diagnosing model diagnostics","volume":"82","author":"Karlsson","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.dmpk.2021.100403_bib31","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","article-title":"Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method","volume":"24","author":"Hooker","year":"2007","journal-title":"Pharm Res (N Y)"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100403_bib32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput Methods Progr Biomed"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100403_bib33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput Methods Progr Biomed"},{"issue":"6","key":"10.1016\/j.dmpk.2021.100403_bib34","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/hep.1840030604","article-title":"Determinants of drug disposition in patients with cirrhosis","volume":"3","author":"Huet","year":"1983","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.dmpk.2021.100403_bib35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/00002018-200528060-00005","article-title":"Dose adjustment in patients with liver disease","volume":"28","author":"Delc\u00f2","year":"2005","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100403_bib36","first-page":"263","article-title":"Hypoxic hepatitis: a review and clinical update","volume":"4","author":"Waseem","year":"2016","journal-title":"J\u00a0Clin Transl Hepatol"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100403_bib37","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/106002809402800319","article-title":"Theophylline disposition in Korean patients with congestive heart failure","volume":"28","author":"Jeong","year":"1994","journal-title":"Ann Pharmacother"},{"issue":"Suppl 1","key":"10.1016\/j.dmpk.2021.100403_bib38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/1043-6618(90)90846-6","article-title":"The effect of sex and cardiac failure on the pharmacokinetics of a slow-release theophylline formulation in the elderly","volume":"22","author":"Cuzzolin","year":"1990","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.dmpk.2021.100403_bib39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0090-9556(25)08515-0","article-title":"Characterization of human liver cytochromes P-450 involved in theophylline metabolism","volume":"20","author":"Sarkar","year":"1992","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmpk.2021.100403_bib40","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.2042-7158.1988.tb06301.x","article-title":"Theophylline metabolism by human, rabbit and rat liver microsomes and by purified forms of cytochrome P450","volume":"40","author":"McManus","year":"1988","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100403_bib41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2125.1995.tb04455.x","article-title":"Metabolism of theophylline by cDNA-expressed human cytochromes P-450","volume":"39","author":"Ha","year":"1995","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.dmpk.2021.100403_bib42","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/0006-2952(88)90423-6","article-title":"Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies","volume":"37","author":"Robson","year":"1988","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.dmpk.2021.100403_bib43","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0090-9556(25)08424-7","article-title":"Theophylline N-demethylations as probes for P4501A1 and P4501A2","volume":"22","author":"Sarkar","year":"1994","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmpk.2021.100403_bib44","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0026-895X(24)12053-6","article-title":"Impaired elimination of propranolol due to right heart failure: drug clearance in the isolated liver and its relationship to intrinsic metabolic capacity","volume":"28","author":"Ng","year":"2000","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmpk.2021.100403_bib45","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/sj.bjp.0704933","article-title":"Hypoxia-induced down-regulation of CYP1A1\/1A2 and up-regulation of CYP3A6 involves serum mediators","volume":"137","author":"Fradette","year":"2002","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100403_bib46","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/sj.bjp.0702795","article-title":"Effect of hypoxia alone or combined with inflammation and 3-methylcholanthrene on hepatic cytochrome P450 in conscious rabbits","volume":"128","author":"Kurdi","year":"1999","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100403_bib47","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1253\/jcj.53.175","article-title":"Analysis of acute and chronic heart failure in view of hepatic oxygen supply-demand relationship using hepatic venous oxygen saturation","volume":"53","author":"Matsuda","year":"1989","journal-title":"Jpn Circ J"},{"issue":"6","key":"10.1016\/j.dmpk.2021.100403_bib48","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.RES.41.6.787","article-title":"Effects of acute, passive hepatic congestion on blood flow and oxygen uptake in the intact liver of the cat","volume":"41","author":"Lautt","year":"1977","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100403_bib49","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000129204","article-title":"Changes in hepatic hemodynamics and oxygen consumption after partial hepatic congestion in dogs","volume":"24","author":"Yamamoto","year":"1992","journal-title":"Eur Surg Res"},{"issue":"6","key":"10.1016\/j.dmpk.2021.100403_bib50","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/FTD.0000000000000787","article-title":"Differences in theophylline clearance between patients with chronic hepatitis and those with liver cirrhosis","volume":"42","author":"Kurata","year":"2020","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100403_bib51","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/03602530903286476","article-title":"Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2","volume":"42","author":"Zhou","year":"2010","journal-title":"Drug Metab Rev"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100403_bib52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00008571-199204000-00004","article-title":"Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1","volume":"2","author":"Gu","year":"1992","journal-title":"Pharmacogenetics"},{"issue":"7","key":"10.1016\/j.dmpk.2021.100403_bib53","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1128\/AAC.42.7.1751","article-title":"Effects of DU-6859a, a new quinolone antimicrobial, on theophylline metabolism in in\u00a0vitro and in\u00a0vivo studies","volume":"42","author":"Niki","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100403_bib54","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2165\/00003088-199223020-00004","article-title":"Pharmacokinetic drug interactions of macrolides","volume":"23","author":"Periti","year":"1992","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmpk.2021.100403_bib55","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1248\/bpb.16.501","article-title":"Population pharmacokinetics of theophylline. II: intravenous infusion to patients with stable chronic airway obstruction","volume":"16","author":"Yano","year":"1993","journal-title":"Biol Pharm Bull"},{"issue":"11","key":"10.1016\/j.dmpk.2021.100403_bib56","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1248\/bpb.18.1590","article-title":"Population pharmacokinetics of theophylline. III. Premarketing study for a once-daily administered preparation","volume":"18","author":"Tanigawara","year":"1995","journal-title":"Biol Pharm Bull"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436721000240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436721000240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:56:02Z","timestamp":1761162962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436721000240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":56,"alternative-id":["S1347436721000240"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2021.100403","relation":{},"ISSN":["1347-4367"],"issn-type":[{"type":"print","value":"1347-4367"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced theophylline clearance due to hepatic congestion secondary to right heart failure - A population pharmacokinetic study","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2021.100403","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100403"}}